Tamper resistant oral dosage forms containing an embolizing agent

• US 20100099696A1
• Filed: 10/13/2009
• Published: 04/22/2010
• Est. Priority Date: 10/16/2008
• Status: Abandoned Application

• Current Assignee: University of Tennessee Research Foundation (University of Teesside)
• Original Assignee: University of Tennessee Research Foundation (University of Teesside)
• Inventors: Johnson, James R., Qu, Wen, Soscia, Anthony Edward, Peng, Yingxu, Shukla, Atul J., Sun, Yichun
• Application Number:
  US12/587,771
• Publication Number:
  US 20100099696A1
• Time in Patent Office: Days
• US Class Current: 514/282
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 25/36 Opioid-abuse

Abstract

Oral dosage form containing a therapeutically effective amount of a drug susceptible to abuse and an effective amount of an embolizing agent which causes the production of a solid or semi-solid embolus or blockage after tampering.

Claims

1. A dosage form for oral administration comprising a therapeutically effective amount of a drug that is susceptible to abuse and an effective amount of an embolizing agent wherein, following tampering of the dosage form and administration of the tampered dosage form to a non-oral site of administration, the embolizing agent forms an embolus or a coagulation at the site of the administration.

2. The dosage form of claim 1 which is a tablet.

3. The dosage form of claim 1 which is a capsule.

4. The dosage form of claim 1 wherein the drug is an analgesic.

5. The dosage form of claim 4 wherein the analgesic is an opioid analgesic.

6. The dosage form of claim 5 wherein the opioid analgesic is selected from the group consisting of morphine, codeine, buprenorphine, hydrocodone, oxymorphone, hydromorphone, tramadol, and oxycodone, or a pharmaceutically acceptable salt.

7. The dosage form of claim 1 wherein the drug is selected from the group consisting of a tranquilizer, a CNS depressant, a CNS stimulant, a sedative hypnotic, and a respiratory agent.

8. The dosage form of claim 1 wherein the embolizing agent is pH sensitive.

9. The dosage form of claim 8 wherein the pH sensitive embolizing agent is a polymer.

10. The dosage form of claim 9 wherein the pH sensitive polymer is selected from the group consisting of copolymers of methyl and butyl methacrylate and dimethylaminoethyl methacrylates, methacrylic acid copolymer dispersion, methacrylic acid copolymer, Type B, methacrylic acid copolymer, Type A, methacrylic acid copolymer, Type C, cellulose acetate trimellitate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, methacrylic acid/ethyl acrylate copolymers, hydroxypropyl methylcellulose succinate-L, hydroxypropyl methylcellulose succinate-M, hydroxypropyl methylcellulose succinate-H, and cellulose acetate phthalate.

11. The dosage form of claim 1 wherein the embolizing agent is temperature sensitive.

12. The dosage form of claim 11 wherein the temperature sensitive embolizing agent is a polymer.

13. The dosage form of claim 1 wherein the embolizing agent is an agent that causes formation of an embolus when contacted with a biological fluid other than gastric fluid.

14. The dosage form of claim 13 wherein the embolizing agent is thrombin or fibrinogen.

15. The dosage form of claim 1 wherein the embolizing agent is sequestered.

16. The dosage form of claim 13 wherein the sequestered embolizing agent is in the form of a multiplicity of individually coated particles, wherein the coating prevents release of the sequestered embolizing agent when the dosage form has not been tampered.

17. The dosage form of claim 16 wherein the sequestered embolizing agent is dispersed in a matrix that contains a sequestering material that inhibits release of the embolizing agent when the dosage form has not been tampered.

18. The dosage form of claim 1 wherein the presence of the embolizing agent in the dosage form does not decrease the release of the drug from the dosage form when the dosage form is not tampered with and when the dosage form is orally administered.

19. A method for inhibiting abuse of an oral dosage form containing a drug subject to abuse comprising providing a dosage form for oral administration which dosage form comprises a therapeutically effective amount of a drug that is susceptible to abuse and an effective amount of an embolizing agent wherein, following tampering of the dosage form and administration of the tampered dosage form to a non-oral site of administration, the embolizing agent forms an embolus or a coagulation at the site of the administration.

20. A method for making an oral dosage form that is resistant to abuse comprising combining a therapeutically effective amount of a drug that is susceptible to abuse and an amount of an embolizing agent that is effective to cause the formation of an embolus or a coagulation when the dosage form is tampered with and administered to a non-oral site of administration.